Fungal infections and the cancer patient

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 4, 1997, Pages

  Ribaud, P ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Amphotericin B; Antifungal; Aspergillus; Cancer; Candida; Fluconazole; Immunocompromised; Itracon azole; Prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; SAPERCONAZOLE;

ASPERGILLOSIS; CANCER; CANDIDIASIS; CHEMOPROPHYLAXIS; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; PRIORITY JOURNAL; RIGOR;

EID: 0030757937     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00150-0     Document Type: Conference Paper

References (37)

1. Sternberg S. The emerging fungal threat. Science 1994, 266, 1632-1634.
2. Meunier F. Targeting fungi: a challenge. Am J Med 1995, 99(Suppl 6A), 605-675.
3. Saral R. Candida and aspergillus infections in immunocompromised patients: an overview. Rev Infect Dis 1991, 13, 487-492.
4. Perfect JR. Management of the immunocompromised patient: impact of fungal infections. Rev Infect Dis 1991, 13, 473.
5. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992, 11, 287-291.
6. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991, 91(Suppl 3B), 86S-89S.
7. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992, 11, 99-109.
8. Cohen J, Denning DW, Viviani MA. EORTC Invasive Fungal Infections Cooperative Group. Epidemiology of invasive asperillosis in European cancer centres (letter). Eur J Clin Microbiol Infect Dis 1993, 12, 392-893.
9. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990, 17(Suppl 6), 10-13.
10. Miller PJ, Wenzel RP. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections. J Infect Dis 1987, 156, 471-477.
11. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148, 2642-2645.
12. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985, 7, 646-655.
13. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen in immunocomproised patients. Ann Intern Med 1979, 91, 539-543.
14. Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986, 24, 581-584.
15. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: factors associated with etiology (albicans vs. non-albicans) and survival. Abstracts of the IDSA 34th Annual Meeting [abstract]. Infectious Diseases Society of America, 196, 40.
16. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990, 12, 1147-1201.
17. Denning DW, Marinus A, Cohen J, et al. Risk factors and outcome from invasive aspergillosis (IA). Programs and abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract]. American Society for Microbiology, 1996, 227.
18. Graybill JR. Future directions of antifungal chemotherapy. Clin Infect Dis 1992, 14(Suppl 1), S170-S181.
19. Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis 1991, 13, 493-495.
20. Walsh TJ, Hathorn JW, Sobel JD, et al. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candiasis. N Engl J Med 1991, 324, 1026-1031.
21. Talbot GH, Weiner MH, Gerson SL, Provencher M, Hurwitz S. Serodiagnosis of invasive aspergillosis in patients with hematologic malignancy: validation of the Aspergillus fumigatus antigen radioimmunoassay. J Infect Dis 1987, 155, 12-27.
22. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994, 97, 509-514.
23. Perfect JR, Klotman ME, Gilbert CC, et al. . Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992, 165, 891-897.
24. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982, 72, 101-111.
25. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989, 86, 668-672.
26. Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984, 20, 1194-1195.
27. Merz WG, Sandford GR. Isolation and characterization of a polyene resistant variant of C. tropicalis. J Clin Microbiol 1979, 9, 677-680.
28. Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropencic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87, 803-808.
29. Freifeld A, Pizzo P. Colony-stimulating factors and neutropenia: intersection of data and clinical relevance (editorial). J Natl Cancer Inst 1995, 87, 781-782.
30. Ribaud P, Gluckman E. Critical review of lipid amphotericin B formulations as treatment of invasive aspergillosis in patients with hematologic disorders and bone marrow transplantations. J Mycol Med 1996, 6(Suppl 1), 17-20.
31. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic patients. Antimicrob Ag Chemother 1987, 31, 11-15.
32. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995, 50, 658-690.
33. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994, 120, 913-918.
34. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326, 845-851.
35. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325, 1274-1277.
36. Rex JH, Bennett JE, Sugar AM, et al. The Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994, 331, 1325-1330.
37. Perfect JR. Antifungal prophylaxis: to prevent or not (editorial). Am J Med 1993, 94, 233-234.